<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01698658</url>
  </required_header>
  <id_info>
    <org_study_id>2011-201</org_study_id>
    <secondary_id>NCI-2012-01745</secondary_id>
    <secondary_id>P30CA022453</secondary_id>
    <nct_id>NCT01698658</nct_id>
  </id_info>
  <brief_title>Ultrasound Tomography Using SoftVue in Diagnosing Women With Breast Cancer</brief_title>
  <official_title>Clinical Data Collection for Initial Evaluation of SoftVue: a Novel Ultrasound Breast Scanner</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Barbara Ann Karmanos Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Barbara Ann Karmanos Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical trial studies ultrasound tomography using SoftVue in diagnosing women with&#xD;
      breast cancer. New diagnostic procedures, such as ultrasound tomography using SoftVue, may&#xD;
      help find and diagnose breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. Determine the in-vivo imaging potential of SoftVue through 3-dimensional (3-D) breast&#xD;
      imaging.&#xD;
&#xD;
      II. Acquire data for SoftVue evaluation from a cohort of 100 women receiving standard&#xD;
      ultrasound (US) evaluation as follow-up to mammographic or palpable abnormalities and&#xD;
      construct reflection, sound speed and attenuation images with SoftVue.&#xD;
&#xD;
      III. Evaluate the ability of SoftVue to detect dominant breast findings (i.e. major normal&#xD;
      landmark architecture) or masses previously identified with standard diagnostic evaluation&#xD;
      (palpation, mammography, standard US) using standard clock position and radial distance&#xD;
      measurements from the nipple.&#xD;
&#xD;
      IV. Conduct tomographic (i.e. slice-by-slice) comparison of SoftVue with magnetic resonance&#xD;
      imaging (MRI) findings from a subgroup of 50 patients.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      Patients undergo ultrasound tomography using SoftVue. Some patients also undergo MRI of the&#xD;
      breast.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation the SoftVue system with respect to spatial resolution, contrast, sound speed resolution, and attenuation resolution</measure>
    <time_frame>At time of procedure</time_frame>
    <description>For each type of resolution, observed values will be averaged over slices for each participant and compared to milestone values. The proportion of individuals whose images meet the milestone criteria will be reported with 95% confidence intervals calculated using Wilson's method.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ability of the system to identify pathological features previously identified by other imaging modalities</measure>
    <time_frame>At time of procedure</time_frame>
    <description>The sensitivity of the SoftVue system to identify pathologic features will be estimated with 95% confidence intervals using previous imaging studies as the gold standard.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent agreement between SoftVue (ultrasound tomography classification) and MRI (MR Breast Imaging-Reporting and Data System [BIRADS] classification)</measure>
    <time_frame>At time of procedure</time_frame>
    <description>Will be calculated along with 95% confidence intervals.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sound speed as a percentage measure of dense breast tissue</measure>
    <time_frame>At time of procedure</time_frame>
    <description>Compare measured sound speed values against known values for the range of tissue types imaged (e.g. fatty breasts should have average sound speeds consistent with known speeds for fatty tissue).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">657</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Diagnostic (SoftVue ultrasound tomography)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergo ultrasound tomography using SoftVue. Some patients also undergo MRI of the breast.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>ultrasound tomography</intervention_name>
    <description>Undergo ultrasound tomography using SoftVue</description>
    <arm_group_label>Diagnostic (SoftVue ultrasound tomography)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>magnetic resonance imaging</intervention_name>
    <description>Undergo MRI of the breast</description>
    <arm_group_label>Diagnostic (SoftVue ultrasound tomography)</arm_group_label>
    <other_name>MRI</other_name>
    <other_name>NMR imaging</other_name>
    <other_name>NMRI</other_name>
    <other_name>nuclear magnetic resonance imaging</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Scheduled for mammogram, breast ultrasound and/or breast MRI&#xD;
&#xD;
          -  Breast size less than 22 cm diameter (ring diameter is 22cm)&#xD;
&#xD;
          -  Able to read or understand and provide informed consent&#xD;
&#xD;
          -  Weight &lt; 350lbs (patient bed max weight)&#xD;
&#xD;
          -  Non-pregnant and non-lactating&#xD;
&#xD;
          -  No open breast or chest wounds&#xD;
&#xD;
          -  No active skin infection&#xD;
&#xD;
          -  No serious medical or psychiatric illnesses that would prevent informed consent&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>89 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alit Amit-Yousif, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Barbara Ann Karmanos Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Barbara Ann Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>September 26, 2012</study_first_submitted>
  <study_first_submitted_qc>September 28, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 3, 2012</study_first_posted>
  <last_update_submitted>June 23, 2021</last_update_submitted>
  <last_update_submitted_qc>June 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Barbara Ann Karmanos Cancer Institute</investigator_affiliation>
    <investigator_full_name>Alit Amit-Yousif</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

